Novel Therapies for Acute Myelogenous Leukemia (AML)

Acute Myeloid Leukemia (AML) Awareness Day: Evolving Treatment DirectionsПодробнее

FDA D.I.S.C.O.: A new treatment for acute myelogenous leukemiaПодробнее

Novel targeted therapies for Acute Myeloid LeukemiaПодробнее

The emergence of novel antibodies, CAR-T and CAR-NK therapies in AMLПодробнее

2022 New + Emerging Treatments: Acute Myeloid LeukemiaПодробнее

How the AML treatment landscape has evolved with the use of novel combination therapiesПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Novel Therapies in Myeloid NeoplasmsПодробнее

Discovering new avenues for the treatment of Acute Myeloid LeukemiaПодробнее

From MDS to AML: What Every Patient Needs to Know 11/28/17Подробнее

Webinar: Childhood Acute Myeloid Leukemia 2018Подробнее

Acute Myeloid Leukemia and New Paths to TreatmentПодробнее

AML Treatment Challenges Who, When, and HowПодробнее

Role of FLT3 Inhibitors and Other Novel Agents in AMLПодробнее

New Frontiers and Emerging Treatments for Acute Myeloid Leukemia | WebcastПодробнее

Novel therapies in AML and MDSПодробнее

Targeted Therapy for Acute Myeloid LeukemiaПодробнее

Acute Myeloid Leukemia: Debate on Standard of Care for Patients ≥ 60 YearsПодробнее

Acute Myeloid Leukemia: Novel Therapies for Newly Diagnosed Patients - Part 2Подробнее

Acute Myeloid Leukemia: Novel Therapies for Newly Diagnosed Patients - Part 1Подробнее